Trials / Unknown
UnknownNCT06321692
Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- European Institute of Oncology · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is for patients with neuroendocrine tumours (NET) with or without carcinoid syndrome followed by NET Unit of European Institute of Oncology. The objective of the trial is to evaluate biochemical markers of myocardial injury (high-sensitive troponins), haemodyinamic markers (pro-brain natriuretic peptide (BNP), N-terminal (NT)-BNP (NT-proBNP)), and markers of fibrosis (Suppression of Tumorigenicity 2 (ST2) in patients with neuroendocrine tumours (NET) with or without carcinoid syndrome.
Detailed description
The main aim of this study is to evaluate blood levels of biomarkers of cardiac damage (ultra-sensitive troponin I), hemodynamic impairment (BNP, NT-proBNP), and cardiac fibrosis (ST2) in patients with diagnosed neuroendocrine tumours (NET) with or without carcinoid syndrome The secondary objective is to correlate the levels of the above markers with the presence/entity of cardiac involvement and its progression over time. All patients will undergo: * a baseline assessment including: * blood sampling for US-Troponin I, BNP, NT-proBNP, ST2 * cardiological evaluation including ECG and echocardiogram * a three-monthly revaluation of these markers * a six monthly cardiological reassessment with a echocardiogram
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Evaluation of blood levels of biomarkers of cardiac damage | Evaluation of ultra-sensitive troponin I, BNP, NT-proBNP, and ST2 in patients with diagnosed neuroendocrine tumours (NET) with or without carcinoid syndrome |
Timeline
- Start date
- 2019-10-09
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2024-03-20
- Last updated
- 2024-03-20
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06321692. Inclusion in this directory is not an endorsement.